Scotia Holdings Plc.

Efamol Holdings Plc

Efamol Limited

Other

Laxdale Limited

Viatris Gmbh & Co Kg

The Wkk Trust

The Wwk Trust of 225-235 High Street

Kilgowan Limited

Soctia Holdings Plc

Efamol Holding Plc

Protarga, Inc.

John C. M. Stewart

Michael D. Winther

David F. Horrobin

David F Horrobin

Mehar S Manku

Philip Knowles

John C Stewart

Austin McMordie

Yung-Sheng Huang

Catherine A Scott

Cari Loder

Brenda E Reynolds

Andrea Pitt

Peter Redden

Michael D Winther

Paul Andrew Wakefield

Michel E Begin

Graham Cooper

Paul Bradley

Lars Lindmark

John B Cloughley

Hans-Jurgen Tritschler

Stephen C Cunnane

Frank Corrigan

Michael J Finnen

Christina Gouaille

Alfred C Buck

Barbara Jacqueline Stordy

Yung S Huang

Norman Cameron

Robert A Casper

Charles Stewart

Mary Cotter

Hugh Carmichael

John C M Stewart

A method of treating pain by the co-administration of an antidepressant together with one or more precursors or inducers of neurotransmitters, particularly amino acids selected from L-phenylalanine, L-tyrosine, L-tryptophan and L-DOPA.

Treatment of pain

Compostions of GLA and/or other EFAs with TA or related compounds, and their use in therapy or nutrition or in preparation of composition for therapy or nutrition, especially to improve cell membrane EFA concentration and/or (particularly in diabetic complications) impaired nerve function and blood flow.

Therapeutic and dietary compositions containing essential fatty acids and bioactive disulphides

This invention relates to the treatment of depression by administering a composition of essential fatty acids of eicosapentaenoic (EPA) and steraridonic (SA) acids.

Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid

A nutritional, cosmetic or pharmaceutical formulation comprising esters of polyethylene glycol in which the polyethylene glycol chain is terminated at one end by a polyunsaturated fatty acyl group, preferably C -C and at the other end by a C -C alkyl group, preferably a methyl group.

Polyethylene glycol esters of polyunsaturated fatty acids

1,3-propane diol esters and ethers and methods for their use in drug delivery

Eicosapentaenoic acid or any appropriate derivative (EPA) is disclosed in combination with arachidonic acid (AA) or an AA precursor, selected from DGLA and GLA, to give a pharmaceutical formulation.

Therapeutic combinations of fatty acids

Treatment of fatigue, head injury and stroke

The use in preparation of a medicament for treating and preventing the side effects of anti-cancer chemotherapy of a polyunsaturated fatty acid with a carbon chain length of 14 to 26 and with 2 to 6 double bonds in the molecule in cis or trans configuration, and a method of such treatment or prevention wherein said fatty acid is used as an active.

Fatty acid treatment

Oral combinations of hydroxocobalamin and folic acid

A pharmaceutical preparation for the treatment of schizophrenia and/or tardive dyskinesia using an oil comprising eicosapentaenoic acid (EPA) and/or stearidonic acid (SA) in amounts of more than 20%, preferably more than 40% and very preferably more than 70% by weight of the total (preferably of the total unsaturated) fatty acids present.

Compounds of structure (I), and when for use in therapy: where R,is an acyl group derived from a C,fatty acid with two or more cis or trans double bonds and particularly an n-6 or n-3 series EFA or conjugated linoleic acid, or columbinic acid, or parinaric acid and R,is as R,the same or different, or any other nutrient, drug or other bioactive residue released as the active in the body and R,is either hydrogen, fully hydrocarbon, or containing heteroatoms, preferably an alkyl group particularly a C,-C,alkyl group.

Fatty acid esters as bioactive compounds

This invention relates to the administration of arachidonic acid or docosahexaenoic acid or precursors thereof to children or pregnant women for the treatment or prevention of dyspraxia.

Use of arachidonic acid and/or docosahexanoic acid for the treatment of dyspraxia

Optimum conditions for prostaglandin synthesis are provided by internally administering an ascorbic-6-acid ester of gamma-linolenic acid or an ascorbic-6-acid ester of dihomo-gamma-linolenic acid.

Methods of treatment using ascorbyl gamma linolenic acid or ascorbyl dihomo-gamma-linolenic acid

Use of 6-desaturated n-6 fatty acids, especially gammalinolenic acid (GLA), dihomogammalinolenic acid (DGLA) or arachidonic acid (AA), together with a pharmaceutically acceptable material reducing intracellular levels of sorbitol in the body, particularly an aldose reductase inhibitor, in the treatment of (including prophylactic treatment), and in the preparation of medicaments for the treatment of (including prophylactic treatment), the long-term complications of diabetes mellitus. Pharmaceutical compositions of said materials. The ascorbate esters of 6-desaturated n-6 fatty acids (other than GLA or DGLA) per se.

Compositions for treatment of diabetic complications

Growing community of inventors

Guildford, United Kingdom

David F Horrobin